This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Complix NV (protein therapeutics for cancer and autoimmune diseases) raised €12mm ($15.5mm) through its Series B round co-led by new investors Edmond de Rothschild Investment Partners, GIMV, and Biotech Fund Flanders (managed by GIMV). LRM, Omnes Capital, Vesalius Biocapital, Gemma Frisius Fund, TrustCapital, Vinnof, Baekeland Fund, CRP-Santé, and members of Complix’s management also participated. One executive from Edmond de Rothschild and GIMV will join the company's board.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?